'Mod­er­na will be a rare dis­ease com­pa­ny,' CEO says, as mR­NA com­pa­ny plots ex­pan­sion in ge­net­ic dis­eases and eyes n-of-1 treat­ments

Just a few years ago, Mod­er­na faced a cho­rus of doubts over whether its ex­per­i­men­tal mR­NA tech­nol­o­gy would ever work well enough to be­come a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.